ArticleInternational journal of molecular medicine2018
miR-152 is involved in the proliferation and metastasis of ovarian cancer through repression of ERBB3.
Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- RETRACTION: miR-135a Targets SMAD2 to Promote Osteosarcoma Proliferation and Migration.Journal of oncology · 2026Article
- Regulation and function of microRNA-152 in various types of cancers: its upstream regulators and downstream targets.Clinical and experimental medicine · 2025Review
- 7‑Difluoromethoxyl‑5,4'‑di‑n‑octylygenistein targets the STAT3 pathway by upregulating microRNA‑152‑3p expression to inhibit self‑renewal and tumor growth in non‑small cell lung carcinoma.Oncology reports · 2025Article
- The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.Frontiers in immunology · 2024Review
- MicroRNA152-3p Protects Against Ischemia/Reperfusion-Induced Bbb Destruction Possibly Targeting the MAP3K2/JNK/c-Jun Pathway.Neurochemical research · 2023Article
- Exosomal transfer of miR-548aq-3p confers cisplatin resistanceAmerican journal of cancer research · 2023Article
- LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b.Molecular medicine (Cambridge, Mass.) · 2022Article
- NUF2 overexpression contributes to epithelial ovarian cancer progressionFrontiers in oncology · 2022Article
- A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers.Frontiers in oncology · 2022Article
- High expression level of miR-1260 family in the peripheral blood of patients with ovarian carcinoma.Journal of ovarian research · 2021Article
- METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246.Cell death discovery · 2021Article
- Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells.Oncology letters · 2021Article
- Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.Human cell · 2021Article
- The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.International journal of molecular sciences · 2020Review
- A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets.Oncology letters · 2020Article
- Article
- miR-152 inhibits the proliferation and invasion of chordoma cells by targetingThe Journal of international medical research · 2019Article
- MicroRNA-152 Acts as a Tumor Suppressor MicroRNA by Inhibiting Krüppel-Like Factor 5 in Human Cervical Cancer.Oncology research · 2019Article
- Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.Frontiers in cell and developmental biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) participate in post-transcriptional regulation by targeting the 3' untranslated region of target genes that are involved in diverse biological processes. To the best of our knowledge, the association between miR‑152 and ERBB3 in ovarian cancer remains unclear. In the present study, a negative correlation between miR‑152 and ERBB3 in ovarian cancer was observed. The luciferase reporter gene assay results demonstrated that miR‑152 negatively regulated ERBB3 in SKOV3 and OVCAR3 ovarian cancer cells. Furthermore, our results revealed that miR‑152 suppressed the ability of ovarian cancer cell proliferation, migration and invasion, and promoted apoptosis through inhibiting ERBB3 in vitro. Therefore, in the present study, miR‑152 was found to be involved in the proliferation and metastasis of ovarian cancer cells through repression of ERBB3 expression. Therefore, miR‑152 may be a potential therapeutic target for the treatment of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.